SUPERNUS PHARMACEUTICALS, INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31)
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) of $269.80 million as of 2018-01-01, per its 10-K filed 2020-02-28.
Discontinued › Notes
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 · last filed 2020-02-28
- 2018-01-01: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) $269.80M.
- 2017-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) $269.80M.
- 2017-01-01: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) $192.15M.
- 2016-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) $192.15M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) |
|---|---|
| 2018-01-01 | $269.80M 10-K · filed 2020-02-28 |
| 2017-12-31 | $269.80M 10-Q · filed 2019-05-10 |
| 2017-01-01 | $192.15M 10-K · filed 2020-02-28 |
| 2016-12-31 | $192.15M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |